In lung cancer, SIRT3 enhances the sensitivity of lung cancer cells to cisplatin by deacetylating mutant p53 in small-cell lung cancer and elevating the FOXO3α/chromatin licensing and DNA replication factor 1 (CDT1) axis in lung cancer (99, 100). Here, SIRT3 is linked to lung carcinoma.